KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM, L3
First oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted to ENDO2026 and first oral long-acting PTH peptide replacement tablet for hypoparathyroidism – Expanded 50/50 partnership; intention to file IND in late 2026; data submitted to ENDO2026 first
News, Material Contracts
First Oral Anabolic (Bone Building) Peptide Tablet for Postmenopausal Women with Osteoporosis – FDA Type A Endpoint Alignment in July 2025
Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
Earnings Release
Announces Second Quarter 2025 Financial Results and Business Updates
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
PRE 14A
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence